$LGND insider trading
Over the last 12 months, Ligand Pharmaceuticals insiders reported no purchases and 34 sales totaling $32.7M across SEC Form 4 filings. 65% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $32.7M 34 events
- Events · 12m
- 34 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 65% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Espinoza OctavioChief Financial Officer · O | ▼ Sale | 31,641 | $292.06 | $9.2M | -53.3% | plan |
| Aug 12, 2026 | Haas JasonD | ▼ Sale | 7,138 | $292.81 | $2.1M | -64.2% | — |
| Aug 3, 2026 | Reardon AndrewCLO & Secretary · O | ▼ Sale | 5,000 | $288.99 | $1.4M | -10.7% | plan · 10 tranches |
| Jul 1, 2026 | Reardon AndrewCLO & Secretary · O | ▼ Sale | 5,000 | $313.28 | $1.6M | -10.7% | plan · 8 tranches |
| Jun 16, 2026 | Sabba Stephen LD | ▼ Sale | 2,145 | $254 | $545K | -6% | — |
| Jun 12, 2026 | Haas JasonD | ▼ Sale | 6,461 | $255.58 | $1.7M | -56.5% | 2 tranches |
| Jun 11, 2026 | Aryeh JasonD | ▼ Sale | 5,000 | $250 | $1.3M | -4.6% | 2 tranches |
| Jun 10, 2026 | LAMATTINA JOHN LD | ▼ Sale | 4,591 | $250.88 | $1.2M | -14.5% | 4 tranches |
| Jun 1, 2026 | Reardon AndrewCLO & Secretary · O | ▼ Sale | 200 | $230.41 | $46K | -0.5% | plan |
| Jun 1, 2026 | Reardon AndrewCLO & Secretary · O | ▼ Sale | 1,216 | $229.47 | $279K | -2.8% | plan |
| Jun 1, 2026 | Reardon AndrewCLO & Secretary · O | ▼ Sale | 584 | $228.57 | $133K | -1.3% | plan |
| Jun 1, 2026 | Reardon AndrewCLO & Secretary · O | ▼ Sale | 400 | $226.78 | $91K | -0.9% | plan |
| Jun 1, 2026 | Reardon AndrewCLO & Secretary · O | ▼ Sale | 1,432 | $225.97 | $324K | -3.2% | plan |
| Jun 1, 2026 | Reardon AndrewCLO & Secretary · O | ▼ Sale | 677 | $225.2 | $152K | -1.5% | plan |
| Jun 1, 2026 | Reardon AndrewCLO & Secretary · O | ▼ Sale | 491 | $223.95 | $110K | -1.1% | plan |
| May 1, 2026 | Reardon AndrewCLO & Secretary · O | ▼ Sale | 5,000 | $231.31 | $1.2M | -10.8% | plan · 7 tranches |
| Apr 1, 2026 | KOZARICH JOHN WD | ▼ Sale | 467 | $202.23 | $94K | -1.1% | plan · 5 tranches |
| Apr 1, 2026 | Reardon AndrewCLO & Secretary · O | ▼ Sale | 5,000 | $201.24 | $1.0M | -10.8% | plan · 6 tranches |
| Mar 23, 2026 | Sabba Stephen LD | ▼ Sale | 1,000 | $207.87 | $208K | -3% | — |
| Mar 11, 2026 | Espinoza OctavioChief Financial Officer · O | ▼ Sale | 3,057 | $225 | $688K | -12.7% | plan |
| Mar 6, 2026 | LAMATTINA JOHN LD | ▼ Sale | 2,161 | $200.76 | $434K | -6.6% | late |
| Mar 4, 2026 | Reardon AndrewCLO & Secretary · O | ▼ Sale | 5,000 | $206.35 | $1.0M | -11.9% | plan · 11 tranches |
| Mar 4, 2026 | Espinoza OctavioChief Financial Officer · O | ▼ Sale | 13,423 | $205.83 | $2.8M | -38.3% | plan · 11 tranches |
| Mar 3, 2026 | Sabba Stephen LD | ▼ Sale | 2,034 | $201.5 | $410K | -5.7% | — |
| Mar 2, 2026 | KOZARICH JOHN WD | ▼ Sale | 467 | $200.5 | $94K | -1.1% | plan · 6 tranches |
| Feb 2, 2026 | KOZARICH JOHN WD | ▼ Sale | 467 | $195.91 | $91K | -1.1% | plan · 5 tranches |
| Jan 2, 2026 | KOZARICH JOHN WD | ▼ Sale | 467 | $189.58 | $89K | -1.1% | plan · 5 tranches |
| Dec 12, 2025 | Espinoza OctavioChief Financial Officer · O | ▼ Sale | 1,804 | $188.31 | $340K | -6.4% | — |
| Dec 1, 2025 | KOZARICH JOHN WD | ▼ Sale | 467 | $195.84 | $91K | -1% | plan · 7 tranches |
| Nov 7, 2025 | Gray Nancy RyanD | ▼ Sale | 6,571 | $205.45 | $1.4M | -44.8% | 2 tranches |
| Nov 7, 2025 | LAMATTINA JOHN LD | ▼ Sale | 4,179 | $205.45 | $859K | -12% | 2 tranches |
| Nov 3, 2025 | KOZARICH JOHN WD | ▼ Sale | 467 | $191.05 | $89K | -1% | plan · 4 tranches |
| Oct 1, 2025 | KOZARICH JOHN WD | ▼ Sale | 467 | $179.44 | $84K | -1% | plan · 4 tranches |
| Sep 23, 2025 | Aryeh JasonD | ▼ Sale | 10,000 | $170.81 | $1.7M | -12.6% | 3 tranches |
| Sep 2, 2025 | KOZARICH JOHN WD | ▼ Sale | 467 | $162.26 | $76K | -1% | plan · 3 tranches |
Every $LGND filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Ligand Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $LGND feed.